Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management

Pregnancy-associated atypical hemolytic uremic syndrome is a systemic disease associated with high morbidity and mortality rates, caused by dysregulation of the alternative complement pathway, leading to uncontrolled complement activation resulting in thrombotic microangiopathy. This condition can b...

Full description

Saved in:
Bibliographic Details
Published inJournal of nephrology Vol. 28; no. 5; pp. 641 - 645
Main Authors De Sousa Amorim, Erika, Blasco, Miquel, Quintana, Luis, Sole, Manel, de Cordoba, Santiago Rodríguez, Campistol, Josep Maria
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.10.2015
Subjects
Adult
Antibodies, Monoclonal, Humanized - administration & dosage
Atypical Hemolytic Uremic Syndrome - diagnosis
Atypical Hemolytic Uremic Syndrome - drug therapy
Biopsy
Case Report
Diagnosis, Differential
Disease Management
Female
Follow-Up Studies
Humans
Kidney - pathology
Medicine
Medicine & Public Health
Nephrology
Pregnancy
Pregnancy Complications - drug therapy
Remission Induction
Urology
Pregnancy
Eculizumab
Post-partum
Hemolytic uremic syndrome
Online AccessGet full text

Cover

More Information
Summary:Pregnancy-associated atypical hemolytic uremic syndrome is a systemic disease associated with high morbidity and mortality rates, caused by dysregulation of the alternative complement pathway, leading to uncontrolled complement activation resulting in thrombotic microangiopathy. This condition can be effectively treated by anti-C5 therapy, which controls complement activation. Treatment can be safely discontinued after complete remission and resolution of the precipitating cause, especially in patients with a low-risk genetic profile.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1121-8428
1724-6059
DOI:10.1007/s40620-015-0173-5